Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Retina, Basic & Translational Research, Health Economics and Policy

ROP Protection

Around one in every 10 births recorded worldwide are premature, meaning that millions of infants are at heightened risk of certain health issues, including retinopathy of prematurity (ROP), every year. ROP can be treated by laser, cryotherapy, or intravitreal injections of anti-VEGF, but access to such options is reliant on medical infrastructure and trained personnel, which may not adequate low- and middle-income countries, where premature births are more common.

Now, a team of researchers from the University of Regensburg, Germany, has developed and tested (in mice) a nanoparticle-based therapeutic that prevents ROP with a single intravenous injection, allowing for healthy retinal development (1). The active agent is cyclosporin A, which inhibits the excessive vascularization and inflammation that causes retinal damage and lasting vision problems.

But the real key to the solution is the ability of the nanoparticles to target and then accumulate in the retinal pigment epithelium (RPE) to deliver the cyclosporin A where it is needed. The solution is technical but elegant. First, the nanoparticles in question are made from lipid nanocapsules that are similar to very low density lipoproteins, and therefore are able to traverse the biological barriers en route to the RPE. Second, the nanocapsules have a shell and core that promote infiltration and uptake through the choroid. Third, a specific sequence of amino acids (cyclo-RGD) preferentially binds to two cell surface integrin receptors expressed by RPE and endothelial cells, allowing the nanoparticles to target multiple RPE targets, promoting accumulation and biological effect.

Importantly, this advanced targeting approach facilitates intravenous injection, removing the need for trained personnel or specialized equipment. The researchers say they set out to develop a simple, affordable, accessible, and effective treatment for ROP – and with further clinical research and testing, this clever nanoparticle-based solution could represent a viable alternative for low- and middle-income countries, preventing millions of premature infants from developing ROP.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. M Bohley et al., Sci Adv, 8, eabo6638 (2022). PMID: 36149956.
About the Author
Geoffrey Potjewyd

Associate Editor, The Ophthalmologist

The lion’s share of my PhD was spent in the lab, and though I mostly enjoyed it (mostly), what I particularly liked was the opportunity to learn about the latest breakthroughs in research. Communicating science to a wider audience allows me to scratch that itch without working all week only to find my stem cell culture has given up the ghost on the Friday (I’m not bitter). Fortunately for me, it turns out writing is actually fun – so by working for Texere I get to do it every day, whilst still being an active member of the clinical and research community.

Related Product Profiles
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Subspecialties Retina
ForeseeHome® – remote monitoring to help detect wet AMD earlier and improve outcomes

| Contributed by Notal Vision

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register